News coverage about Eli Lilly and (NYSE:LLY) has trended somewhat positive on Wednesday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Eli Lilly and earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.5681531874283 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment’s rankings:
- Lilly: Jardiance Reduces Risk Of Cardiovascular Death In Type 2 Diabetes And PAD (rttnews.com)
- Former Eli Lilly Executive Is Trump’s Choice for Health Secretary (nytimes.com)
- Trump nominates former drug company executive Alex Azar as next Health and Human Services secretary (cnbc.com)
- President Donald Trump picks former top drug company and government executive to be his next health secretary (hosted.ap.org)
- Trump nominates Alex Azar, former Bush official and drug company exec, to lead HHS (washingtontimes.com)
Shares of Eli Lilly and (LLY) opened at $82.49 on Wednesday. Eli Lilly and has a fifty-two week low of $64.18 and a fifty-two week high of $89.09. The company has a market cap of $91,236.74, a price-to-earnings ratio of 20.26, a PEG ratio of 1.83 and a beta of 0.34. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The firm had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. During the same quarter in the previous year, the business posted $0.88 EPS. The company’s quarterly revenue was up 9.0% on a year-over-year basis. sell-side analysts forecast that Eli Lilly and will post 4.22 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.52%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is presently 98.58%.
LLY has been the topic of several research reports. TheStreet raised shares of Eli Lilly and from a “c+” rating to a “b+” rating in a research note on Tuesday, July 25th. Berenberg Bank reissued a “buy” rating and set a $98.00 price target on shares of Eli Lilly and in a research note on Friday, August 4th. Jefferies Group LLC reissued a “buy” rating and set a $89.00 price target (down from $94.00) on shares of Eli Lilly and in a research note on Thursday, August 24th. Piper Jaffray Companies reissued a “buy” rating and set a $103.00 price target on shares of Eli Lilly and in a research note on Thursday, August 31st. Finally, Cowen and Company reissued a “buy” rating and set a $95.00 price target on shares of Eli Lilly and in a research note on Wednesday, October 4th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $89.76.
WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Eli Lilly and (LLY) Share Price” was first posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.themarketsdaily.com/2017/11/15/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-eli-lilly-and-lly-share-price.html.
In related news, major shareholder Lilly Endowment Inc sold 180,000 shares of the company’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $81.06, for a total value of $14,590,800.00. Following the transaction, the insider now owns 123,865,804 shares in the company, valued at approximately $10,040,562,072.24. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the transaction, the senior vice president now owns 43,580 shares in the company, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 772,003 shares of company stock worth $64,837,441. 0.20% of the stock is currently owned by company insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.